Usefulness of corrected SUV max change in metastatic NET lesions (before and after PRRT) obtained by [68Ga]Ga-DOTA-TATE PET/CT as a prognostic factor

#3376

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapeutic option for metastatic neuroendocrine tumor (NET)therapy. The high heterogeneity of the somatostatin receptors (SSTR) density in different NET metastatic lesions and inside single tumors probably influence an clinical outcome. Some studies suggest the response to PRRT assessed on the basis of imaging of SSTR may have a predictive value.

Aim(s): Evaluation of corrected SUVmax change in metastatic NET lesions (before and after PRRT) obtained by [68Ga]Ga-DOTA-TATE PET/CT as a potential prognostic factor.

Materials and methods: 13 patients who underwent 68Ga-DOTATATE PET/CT no longer than 6 months before and 6 months after PRRT were eligible to the analysis. For all measurable metastatic lesions corrected SUVmax (including individual for each patient SUVmax of reference organs normal liver or spleen) before and after PRRT was calculated. Later the mean values per organs were counted and finally the change of SUVmax values in metastatic lesions divided by organs in both PET/CTs were calculated. Those results were correlated with clinical outcome.

Conference:

Presenting Author:

Authors: Opalinska M, Sowa-Staszczak A, Kania-Kuc A, Al Maraih I, Hubalewska-Dydejczyk A,

Keywords: PRRT, NET, outcome, 68Ga-DOTATATE PET/CT, SSTR expression,